IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma

In this study, we synthesized a molecule GA-1MT (GM) composed of indoleamine 2,3-dioxygenase (IDO) inhibitor (1-methyl-d-tryptophan, 1MT) called NLG8189 and gallic acid (GA) and verified its therapeutic effect on B16F10 melanoma cells and an orthotopic tumor-bearing mouse model. The synthesized mole...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Hongmei Liu, Huan Gao, Cheng Chen, Wenyu Jia, Delong Xu, Guan Jiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Subjects:	gallic acid indoleamine 2 3-dioxygenase melanoma chemotherapy immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.904229/full

Similar Items

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
by: Dongquan Xiang, et al.
Published: (2023-06-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01)

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
by: Chiara Suvieri, et al.
Published: (2024-11-01)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
by: Thiara Manuele Alves de Souza, et al.
Published: (2022-04-01)

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies
by: Jiang K, et al.
Published: (2024-08-01)

Tumor Microenvironment‐Activated Nanocomposite for Self‐Amplifying Chemodynamic/Starvation Therapy Enhanced IDO‐Blockade Tumor Immunotherapy
by: Yulong Bian, et al.
Published: (2023-12-01)

The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma
by: E Orecchini, et al.
Published: (2023-12-01)

Tumor Microenvironment‐Responsive Nanoparticles Enhance IDO1 Blockade Immunotherapy by Remodeling Metabolic Immunosuppression
by: Mengna Wang, et al.
Published: (2025-02-01)

1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
by: Huihan Ma, et al.
Published: (2020-09-01)

Dexamethasone Induces the Expression and Function of Tryptophan-2-3-Dioxygenase in SK-MEL-28 Melanoma Cells
by: Marta Cecchi, et al.
Published: (2021-03-01)

Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
by: Nattawut Wongpraparut, et al.
Published: (2021-07-01)

The 14kDa Protein Molecule Isolated from Garlic Suppresses Indoleamine 2, 3-Dioxygenase Metabolites in Mononuclear Cells In vitro
by: Nikoo Shohreh, et al.
Published: (2008-12-01)

Association of Indoleamine 2,3-Dioxygenase (IDO) Activity with Outcome after Cardiac Surgery in Adult Patients
by: Andrea Stieger, et al.
Published: (2024-06-01)

Progesterone decreased indoleamine 2,3-dioxygenase 1(IDO1) expression in early pregnancy chorionic villi and decidua
by: Minyan Yang, et al.
Published: (2021-04-01)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
by: Florent Peyraud, et al.
Published: (2022-01-01)

Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue–Focus on RAGE and IDO1
by: Joanna Tkaczuk-Włach, et al.
Published: (2021-04-01)

IDO1-AhR axis increases T regulatory cells in Plasmodium vivax malaria infection
by: Rafaella Oliveira dos Santos, et al.
Published: (2025-07-01)

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
by: Peng X, et al.
Published: (2022-08-01)

Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
by: Yvonne Grobben, et al.
Published: (2021-01-01)

Calcium Channel Blocker Lacidipine Promotes Antitumor Immunity by Reprogramming Tryptophan Metabolism
by: Yuwen Sheng, et al.
Published: (2025-01-01)

Heat up, silence on: IDO1 gene silencing in THP-1-derived dendritic cells triggered by magnetic hyperthermia
by: Daniela Ferreira, et al.
Published: (2025-08-01)

IDO-Mediated Immune and Metabolic Dysregulation in Schwann Cells Exposed to <i>Mycobacterium leprae</i>
by: Atta Ur Rahman, et al.
Published: (2025-10-01)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
by: Eleonora Panfili, et al.
Published: (2023-04-01)

Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors
by: Xixi Hou, et al.
Published: (2022-10-01)

Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors
by: Chuan Zhou, et al.
Published: (2020-03-01)

Research progress of indoleamine 2,3-dioxygenase 1 in gastric cancer
by: Pei Xiaxia, et al.
Published: (2023-03-01)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma
by: Zikang Xing, et al.
Published: (2024-06-01)

Cooperative Hedgehog/GLI and JAK/STAT signaling drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer
by: Dominik P. Elmer, et al.
Published: (2025-02-01)

Hydrophobic ion pairing and microfluidic nanoprecipitation enable efficient nanoformulation of a small molecule indolamine 2, 3‐dioxygenase inhibitor immunotherapeutic
by: Parisa Badiee, et al.
Published: (2024-01-01)

The crucial function of IDO1 in pulmonary fibrosis: From the perspective of mitochondrial fusion in lung fibroblasts and targeted molecular inhibition
by: Lei Wang, et al.
Published: (2025-06-01)

IDO1 induced macrophage M1 polarization via ER stress-associated GRP78-XBP1 pathway to promote ulcerative colitis progression
by: Zijian Gao, et al.
Published: (2025-04-01)

First-in-Class, Thiosemicarbazide-Based, Dual Inhibitors of Human DNA Topoisomerase IIα and Indoleamine-2,3-Dioxygenase 1 (IDO-1) with Strong Anticancer Properties
by: Barbara Kaproń, et al.
Published: (2022-11-01)

DSS-induced colitis activates the kynurenine pathway in serum and brain by affecting IDO-1 and gut microbiota
by: Li-Ping Zhao, et al.
Published: (2023-01-01)

Kynurenine acts as a signaling molecule to attenuate pulmonary fibrosis by enhancing the AHR-PTEN axis
by: Yi Wang, et al.
Published: (2025-05-01)

Synthesis and activity study of novel N,N-diphenylurea derivatives as IDO1 inhibitors
by: Xi-Xi Hou, et al.
Published: (2023-06-01)

Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor
by: Olga Troitskaya, et al.
Published: (2020-06-01)

Uterine Commensal <i>Peptostreptococcus</i> Species Contribute to IDO1 Induction in Endometrial Cancer via Indoleacrylic Acid
by: Qiong Wang, et al.
Published: (2024-03-01)

Inhibitory effect of human indoleamine 2,3-dioxygenase 1 (hIDO1) by kazinols of 1,3-diphenylpropane derivatives
by: Taehoon Oh, et al.
Published: (2024-09-01)